Use of phosphate-binding agents is associated with a lower risk of mortality

Kidney International

Volumn 84, Issue 5, 2013, Pages 998-1008

  Cannata Andía, Jorge B ^a   Fernández Martín, José L ^a   Locatelli, Francesco ^b   London, Gérard ^c   Gorriz, José L ^d   Floege, Jürgen ^e   Ketteler, Markus ^f   Ferreira, Aníbal ^g   Covic, Adrian ^h   Rutkowski, Boleslaw ⁱ   Memmos, Dimitrios ^j   Bos, Willem Jan ^k   Teplan, Vladimir ^l   Nagy, Judit ^m   Tielemans, Christian ⁿ   Verbeelen, Dierik ^o   Goldsmith, David ^p   Kramar, Reinhard ^q   Martin, Pierre Yves ^r   Wüthrich, Rudolf P ^s   Pavlovic, Drasko ^t   Benedik, Miha ^u   Sánchez, José Emilio ^v   Martínez Camblor, Pablo ^a   Naves Díaz, Manuel ^a   Carrero, Juan J ^w   Zoccali, Carmine ^x   more..

^a UNIVERSITY OF OVIEDO   (Spain)

^b A MANZONI HOSPITAL   (Italy)

^c Centre Hospitalier FH Manhes   (France)

^d HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^e RWTH AACHEN UNIVERSITY   (Germany)

^f KLINIKUM COBURG   (Germany)

^g NOVA MEDICAL SCHOOL   (Portugal)

^h GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

ⁱ MEDICAL UNIVERSITY OF GDANSK   (Poland)

^j Aristotle University of Thessaloniki   (Greece)

^k ST ANTONIUS HOSPITAL   (Netherlands)

^l INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^m UNIVERSITY OF PÉCS   (Hungary)

ⁿ UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^o VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^p KING'S COLLEGE LONDON   (United Kingdom)

^q Klinikum Kreuzschwestern Wels   (Austria)

^r GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^s UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^t SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^u UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^v HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^w KAROLINSKA INSTITUTE   (Sweden)

^x OSPEDALI RIUNITI   (Italy)

more..

Author keywords

dialysis; hyperparathyroidism; hyperphosphatemia; mineral metabolism; mortality risk; phosphate binders

Indexed keywords

ALUMINUM SALT; LANTHANUM CARBONATE; PHOSPHATE BINDING AGENT; SEVELAMER;

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; PROPENSITY SCORE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT INDICATION;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHELATING AGENTS; CHI-SQUARE DISTRIBUTION; EUROPE; FEMALE; HUMANS; HYPERPHOSPHATEMIA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHOSPHATES; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84888348838     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.185     Document Type: Article

References (50)

1. Slatopolsky E, Moe S. 50 years of research and discovery in chronic kidney disease and mineral & bone disorder: the central role of phosphate. Kidney Int Suppl 2011; 121: S1-S2.
2. Goodman WG, Quarles LD. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int 2008; 74: 276-288.
3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; 76(S113): S1-S130.
4. Locatelli F, Cannata-Andia JB, Drueke TB et al. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 2002; 17: 723-731.
5. Floege J, Kim J, Ireland E et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011; 26: 1948-1955.
6. Cannata-Andia JB, Naves-Diaz M. Phosphorus and survival: key questions that need answers. J Am Soc Nephrol 2009; 20: 234-236.
7. Zoccali C, Ruggenenti P, Perna A et al. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol 2011; 22: 1923-1930.
8. Palmer SC, Hayen A, Macaskill P et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011; 305: 1119-1127.
9. Naves-Diaz M, Passlick-Deetjen J, Guinsburg A et al. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transplant 2011; 26: 1938-1947.
10. Pelletier S, Roth H, Bouchet JL et al. Mineral and bone disease pattern in elderly haemodialysis patients. Nephrol Dial Transplant 2010; 25: 3062-3070.
11. Goodman WG. Vascular calcification in chronic renal failure. Lancet 2001; 358: 1115-1116.
12. Roman-Garcia P, Carrillo-Lopez N, Fernandez-Martin JL et al. High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. Bone 2010; 46: 121-128.
13. Hruska K, Mathew S, Lund R et al. Cardiovascular risk factors in chronic kidney disease: does phosphate qualify? Kidney Int Suppl 2011; 79(S121): S9-S13.
14. Wigner NA, Luderer HF, Cox MK et al. Acute phosphate restriction leads to impaired fracture healing and resistance to BMP-2. J Bone Miner Res 2010; 25: 724-733.
15. Foley RN. Phosphorus comes of age as a cardiovascular risk factor. Arch Intern Med 2007; 167: 873-874.
16. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252.
17. Raggi P, Vukicevic S, Moyses RM et al. Ten-year experience with sevelamer and calcium salts as phosphate binders. Clin J Am Soc Nephrol 2010; 5(Suppl 1): S31-S40.
18. Isakova T, Gutierrez OM, Chang Y et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009; 20: 388-396.
19. Winkelmayer WC, Liu J, Kestenbaum B. Comparative effectiveness of calcium-containing phosphate binders in incident US dialysis patients. Clin J Am Soc Nephrol 2011; 6: 175-183.
20. Stel VS, Dekker FW, Zoccali C et al. Instrumental variable analysis. Nephrol Dial Transplant. 2012; in press (doi:10.1093/ndt/gfs310).
21. Goodkin DA, Bragg-Gresham JL, Koenig KG et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003; 14: 3270-3277.
22. Kramer HJ, Saranathan A, Luke A et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol 2006; 17: 1453-1459.
23. Hecking E, Bragg-Gresham JL, Rayner HC et al. Haemodialysis prescription, adherence and nutritional indicators in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19: 100-107.
24. Lopes AA, Tong L, Thumma J et al. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 2012; 60: 90-101.
25. Palmer SC, McGregor DO, Macaskill P et al. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 2007; 147: 840-853.
26. Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008; 74: 1070-1078.
27. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456.
28. Robinson BM, Port FK. International hemodialysis patient outcomes comparisons revisited: the role of practice patterns and other factors. Clin J Am Soc Nephrol 2009; 4(Suppl 1): S12-S17.
29. Eddington H, Hoefield R, Sinha S et al. Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol 2010; 5: 2251-2257.
30. Zitt E, Lamina C, Sturm G et al. Interaction of time-varying albumin and phosphorus on mortality in incident dialysis patients. Clin J Am Soc Nephrol 2011; 6: 2650-2656.
31. Nolan CR, Qunibi WY. Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis. Kidney Int Suppl 2005; 67(S95): S13-S20.
32. Garg JP, Chasan-Taber S, Blair A et al. Effects of sevelamer and calciumbased phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis Rheum 2005; 52: 290-295.
33. Caglar K, Yilmaz MI, Saglam M et al. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 2008; 3: 61-68.
34. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592.
35. Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A et al. Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients. Nephrol Dial Transplant 2011; 26: 2567-2571.
36. Koiwa F, Kazama JJ, Tokumoto A et al. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005; 9: 336-339.
37. Cannata-Andía JB. Aluminium toxicity: its relationship with bone and iron metabolism. Nephrol Dial Transplant 1996; 11(Suppl 3): 69-73.
38. Cannata-Andia JB, Fernandez-Martin JL. The clinical impact of aluminium overload in renal failure. Nephrol Dial Transplant 2002; 17(Suppl 2): 9-12.
39. West SL, Swan VJ, Jamal SA. Effects of calcium on cardiovascular events in patients with kidney disease and in a healthy population. Clin J Am Soc Nephrol 2010; 5(Suppl 1): S41-S47.
40. Bolland MJ, Avenell A, Baron JA et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010; 341: c3691.
41. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441.
42. Langman CB, Cannata-Andia JB. Calcium in chronic kidney disease: myths and realities. Introduction. Clin J Am Soc Nephrol 2010; 5(Suppl 1): S1-S2.
43. Hutchison AJ, Barnett ME, Krause R et al. Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis. Clin Nephrol 2009; 71: 286-295.
44. Wilson R, Zhang P, Smyth M et al. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. Curr Med Res Opin 2009; 25: 3021-3028.
45. Sprague SM, Abboud H, Qiu P et al. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol 2009; 4: 178-185.
46. Sprague SM, Ross EA, Nath SD et al. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol 2009; 72: 252-258.
47. Block GA, Brillhart SL, Persky MS et al. Efficacy and safety of SBR759, a new iron-based phosphate binder. Kidney Int 2010; 77: 897-903.
48. Jean G, Vanel T. Phosphate binders in a European haemodialysis population. Nephrol Dial Transplant 2011; 26: 2057-2058.
49. Fernández-Martín J, Carrero JJ, Benedik M et al. COSMOS: The dialysis scenario of CKD-MBD in Europe. Nephrol Dial Transplant 2012; in press (doi:10.1093/ndt/gfs418).
50. Cannata-Andia JB, Fernandez-Martin JL, Zoccali C et al. Current management of secondary hyperparathyroidism: a multicenter observational study (COSMOS). J Nephrol 2008; 21: 290-298.